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Abstract
Background: Considerable variation in intravenous 5-fluorouracil (5-FU) metabolism can occur due to the wide
range of dihydropyrimidine dehydrogenase (DPD) enzyme activity, which can affect both tolerability and efficacy.
The oral fluoropyrimidine tegafur-uracil (UFT) is an effective, well-tolerated and convenient alternative to
intravenous 5-FU. We undertook this study in patients with locally advanced rectal cancer to evaluate the efficacy
and tolerability of UFT with leucovorin (LV) and preoperative radiotherapy and to evaluate the utility and
limitations of multicenter staging using pre- and post-chemoradiotherapy ultrasound. We also performed a
validated pretherapy assessment of DPD activity and assessed its potential influence on the tolerability of UFT
treatment.
Methods: This phase II study assessed preoperative UFT with LV and radiotherapy in 85 patients with locally
advanced T3 rectal cancer. Patients with potentially resectable tumors received UFT (300 mg/m/
2/day), LV (75 mg/
day), and pelvic radiotherapy (1.8 Gy/day, 45 Gy total) 5 days/week for 5 weeks then surgery 4-6 weeks later. The
primary endpoints included tumor downstaging and the pathologic complete response (pCR) rate.
Results: Most adverse events were mild to moderate in nature. Preoperative grade 3/4 adverse events included
diarrhea (n = 18, 21%) and nausea/vomiting (n = 5, 6%). Two patients heterozygous for dihydropyrimidine
dehydrogenase gene (DPYD) experienced early grade 4 neutropenia (variant IVS14+1G > A) and diarrhea (variant
2846A > T). Pretreatment ultrasound TNM staging was compared with postchemoradiotherapy pathology TN
staging and a significant shift towards earlier TNM stages was observed (p < 0.001). The overall downstaging rate
was 42% for primary tumors and 44% for lymph nodes. The pCR rate was 8%. The sensitivity and specificity of
ultrasound for staging was poor. Anal sphincter function was preserved in 55 patients (65%). Overall and
recurrence-free survival at 3 years was 86.1% and 66.7%, respectively. Adjuvant chemotherapy was administered to
36 node-positive patients (mean duration 118 days).
Conclusion: Preoperative chemoradiotherapy using UFT with LV plus radiotherapy was well tolerated and effective
and represents a convenient alternative to 5-FU-based chemoradiotherapy for the treatment of resectable rectal
cancer. Pretreatment detection of DPD deficiency should be performed to avoid severe adverse events.
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The standard approach for the preoperative treatment of
rectal cancer is intravenous (i.v.) 5-fluorouracil (5-FU)-
based chemoradiotherapy [1-3] (Rich et al, 1995; Lawr-
ence et al, 1997; Bosset et al 2000). 5-FU can be admi-
nistered as either a bolus injection or a continuous
infusion [4] [Smalley 2006]. However, continuous infu-
sion requires specialized pumps, which are inconvenient
for patients, and long-term venous access, which makes
patients susceptible to infections and thrombosis [1,2]
(Rich et al, 1995; Bosset et al, 2000).
The oral fluoropyrimidine UFT (tegafur-uracil) is an
effective, well-tolerated and convenient alternative to i.v.
5-FU that is widely used in the treatment of colorectal
cancer [5] (Borner et al, 2002). A phase I study of preo-
perative UFT with leucovorin (LV) with radiotherapy
identified a maximum tolerated dose of UFT of 350 mg/
m
2/day with LV 90 mg/day [6] (Hoff et al,2 0 0 0 ) .I n
phase II and III trials, UFT (200-350 mg/m
2/day) without
or with LV (15-45 mg/day) and preoperative radiotherapy
(45-50.4 Gy) has shown similar tumor response and
downstaging rates to those using continuous infusion 5-
FU [7-14] (de la Torre et al, 1999, de la Torre et al,2 0 0 8
Feliu et al, 2002; Wang et al, 2005; Fernández-Martos
et al, 2004; Girault 2008; Kundel 2007; Vestermark 2008).
Considerable variation in 5-FU metabolism and out-
come due to the wide range of dihydropyrimidine dehy-
drogenase (DPD) enzyme activity has been observed and
this variability can influence both tolerability and response
to cancer chemotherapy [15] (Seck et al, 2005). Although
deficient DPD activity is rare (approximately 3-5% of
patients), patients with this deficiency may experience
severe and life-threatening adverse events following treat-
ment with 5-FU or oral fluoropyrimidines such as capeci-
tabine [16-18] (Diasio and Johnson, 1999; Van Kuilenburg
et al, 2003; Saif and Diasio, 2006).
We undertook the present multicenter study in patients
with locally advanced rectal cancer to evaluate the efficacy
and tolerability of UFT with LV and preoperative radio-
therapy and to evaluate the utility and limitations of multi-
center staging using pre- and post-chemoradiotherapy
ultrasound. Since little information is available regarding
DPD activity in UFT-treated patients with rectal cancer,
we also performed a validated pretherapy assessment of
DPD activity and assessed its potential influence on the
tolerability of UFT treatment.
Methods
Patients
Eligible patients had pathologically confirmed clinically
resectable stage T3-T4 and N0-N2 adenocarcinoma of
the distal rectum with no distant metastases. Entry cri-
teria were: inferior margin within 15 cm of the anal verge
and palpable on digital examination; World Health Orga-
nization (WHO) performance status 0-2; age 18-80 years;
adequate hematologic (neutrophils >1500/mm
3), hepatic
(bilirubin <2 upper normal limit), and renal (creatinine
<150 μmol/L) function. Patients with prior malignancies
(excluding localized epithelial skin or cervical cancer),
chemotherapy, and/or pelvic radiotherapy were excluded.
The study was approved by local ethics committees and
was conducted according to the Declaration of Helsinki.
Written informed consent was obtained from each
patient before enrollment.
Pretreatment evaluation included a complete medical
history and physical examination (including digital rectal
examination), complete blood count and chemistry profile,
electrocardiogram, detection of DPD activity (requiring a
10 days period), endorectal ultrasound (EUS), endoscopy
with biopsy, chest X-ray, and abdomen-pelvis computed
tomography (CT) scan.
Treatment
Chemotherapy consisted of UFT 300 mg/m
2/day and LV
75 mg/day orally in three divided doses taken at approxi-
mately 8-hour intervals (either 1 hour before or at least 1
hour after food), 5 days/week for 5 weeks (days 1-33). Pel-
vic radiotherapy (daily dose 1.8 Gy), delivered concurrently
with chemotherapy, was delivered using a conventional
four-field box technique (anterior and posterior fields, plus
right and left lateral fields) and with a minimum of 10
megavoltage photons. A total dose of 45 Gy was delivered
to the isocenter of the four fields. The planning target
volume was defined as the clinical target volume, i.e. the
primary tumor, iliac lymph nodes, and mesorectum in
toto, plus a 10-15 mm margin. Diagnostic imaging was
used to define the gross target volume.
Surgical resection was performed 4-6 weeks after com-
pletion of chemoradiotherapy using a standardized techni-
que with mesorectal excision. Postoperative chemotherapy
could be prescribed for patients who were lymph-node
positive and who responded to preoperative treatment.
These patients received 5 cycles of the same UFT with LV
regimen or 5-FU/LV (de Gramont or Mayo clinic regi-
mens) 3-6 weeks after surgery.
Toxicity assessment and dose adjustments
Toxicity, graded using WHO criteria for chemotherapy
and early radiotherapy toxicity, was assessed at weekly
clinic and biologic examinations during chemoradiother-
apy and at the end of treatment [19] (Miller et al, 1981).
Late radiotherapy toxicity was graded according to the
SOMA-LENT criteria [20] (Mornex et al, 1997). In the
event of grade 2-4 adverse events, chemotherapy was
withheld until evidence of hematologic recovery (neutro-
phils ≥ 1500/mm
3 and platelets ≥100 000/mm
3)a n d
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(other than alopecia) to baseline or grade 1. The UFT
dose was reduced by one capsule per day if grade 3/4
toxicity occurred. Radiotherapy was postponed for
1-2 weeks in the event of grade 3 diarrhea that persisted
despite UFT discontinuation; radiotherapy was stopped if
the grade 3/4 diarrhea persisted for longer than 2 weeks.
Evaluation of response
EUS, chest X-ray, and CT scan were performed at base-
line (within 15 days before chemoradiotherapy) and
after the end of chemoradiotherapy (within 7 days
before surgery). Echoendoscopic and pathologic stages
were defined using the tumor node metastasis (TNM)
s t a g i n gs y s t e m( v e r s i o n5 . 0 )[ 2 1 ]( S o b i na n dW i t t e k i n d ,
1997). Initially, it was planned to determine tumor
downstaging by comparing posttreatment ultrasound (u)
TNM stage (EUS) with the preoperative uTNM stage.
However, due to the limitations of preoperative EUS
because of inflammatory effects and tissue modifications
and the limited number of assessable patients, we
focused on pathological results and compared posttreat-
ment pathological (p)TNM stage to preoperative uTNM
stage. Primary tumor and node downstaging were
defined as reductions in T and N stages by at least one
level. No response was defined as similar pTNM and
uTNM classifications. A pCR was defined as the absence
of any residual tumor cells in the operative specimen
[22] (Meterissian et al, 1994). Lymph nodes were exam-
ined after treatment with a clarification solution in
order to aid detection and improve the reliability of the
pathologic N staging. All resected specimens from the
different hospitals were centralized and reexamined in a
reference pathology laboratory for a central review.
Sphincter function was scored according to the Mem-
orial Sloan Kettering Cancer Center scale [23] (Minsky
et al, 1995). Progression-free survival (PFS) and overall
survival (OS) were measured from the time of inclusion
to the time of disease progression and death (or last fol-
low-up), respectively.
Detection of DPD activity
DPYD genotyping included examination of 24 relevant
gene variants potentially involved in DPD deficiency.
Single nucleotide polymorphisms (SNPs) were detected
using a real-time mini-sequencing method [24] (Morel
et al, 2005). Dihydrouracil and uracil plasma concentra-
tions were determined simultaneously using a liquid
chromatography method [25] (Remaud et al, 2005); if
DPD deficiency was suspected, the plasma dihydrouracil:
uracil (UH2:U) ratio was determined [26] (Boisdron-Celle
et al, 2007). UH2:U ratios were assessed as previously
described [27] (Gamelin et al, 1999). When DPD
deficiency was identified, UFT was administered at the
planned dose but both the clinician and patient were
informed of the risk associated with treatment and
appropriate precautions were taken, such as careful mon-
itoring of diarrhea and neutropenia.
Statistics
Using a two-stage design [28] (Simon, 1989) and assum-
ing a tumor downstaging rate of at least 25%, with alpha
and beta errors of 5% and 10%, respectively, 41 patients
were to be enrolled in the first stage of the study. If four
or fewer responses were observed, the treatment would
be considered ineffective and the trial would be stopped.
If five or more responses were observed, 29 additional
patients would be enrolled, for a total of 70 patients. As
numerous patients were not assessable for EUS, 15 addi-
tional patients were recruited with the approval of IERB.
The primary endpoint was the tumor downstaging
rate with 95% confidence interval (CI). Results are
expressed as mean ± standard deviation. Quantitative
variables were compared using the nonparametric
Mann-Whitney test and qualitative variables using Pear-
son’s chi-squared test or Fisher’s exact test. Survival dis-
tributions were estimated using the Kaplan-Meier
methodology. For safety analyses, the worst toxicity
grade per patient in all chemotherapy cycles was used.
All statistical analyses were conducted using Statistical
Package for Social Sciences software (SPSS version 10.0,
Chicago, IL, USA).
Results
Eighty-five patients were enrolled at 15 centers between
July 2002 and January 2004. Eight patients were ineligi-
ble at study entry: four patients had one or more major
protocol violations (liver metastases, n = 3; suspicion of
pulmonary metastases, n = 1; other cancer, n = 1) and
six patients had one or more minor protocol violations
(tumor in the upper rectum, n = 4; age >80 years, n = 1;
vesical papilloma, n = 1). All 85 patients were evaluated
according to the intention-to-treat principle.
Patient characteristics
Patient characteristics at baseline are shown in Table 1.
Four of the 24 known variants of the DPYD gene were
identified. One patient was heterozygous for the -1590T
> C SNP in the promoter region, one was heterozygous
for IVS14+1G > A (G1A [DPYD*2A]), one had 2846A >
T (D949V), and a fourth had 1679 T > G. A further 38
patients were heterozygous for 85 T > C. Uracil plasma
levels were higher than the threshold (15 μg/L) [26]
(Boisdron-Celle et al, 2007) in three of four patients
with variant DPYD (IVS14+1G > A: 36 μg/L; 2846A >
T: 19 μg/L; and 1679 T > G: 25 μg/L).
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Sixty-three patients (74%) completed treatment as planned.
Most patients (92%) received the planned dose of radiother-
apy (median dose 45 Gy, range 18-46.8 Gy). Radiotherapy
was postponed for at least 1 day in 66 patients (78%); dose
reductions were drug related in five patients (6%). The
planned UFT dose was delivered in 48 patients (mean dose
294 ± 24 mg/m
2). Chemotherapy was delayed in nine
patients (11%) and the dose was reduced in 15 patients
(18%) as a result of adverse events, including diarrhea (n =
5), nausea/vomiting (n = 1), stroke (n = 1), dehydration (n =
3), and gastrointestinal effects (n = 1). Only four (5%) of the
85 patients did not undergo surgery: one patient died of a
cerebrovascular stroke (unrelated to treatment) during the
preoperative period; one patient was lost to follow-up; and
the primary tumor was unresectable in two patients because
of local progression. The majority of patients underwent
anterior resection (AR) (n = 54; 63%); abdominoperineal
resection (APR) was necessary in 27 patients (32%).
Safety
Diarrhea was the most common adverse event (60 events,
42 of which were judged to be treatment related). Most
adverse events were mild to moderate in nature. Grade
3/4 adverse events, which occurred in 38 patients (45%),
a r es h o w ni nT a b l e2 .O n l yp a t i e n t sw h ow e r eh e t e r o z y -
gous for variants IVS14+1G > A and 2846A > T experi-
enced very early grade 4 neutropenia and diarrhea related
to UFT. The patient who was heterozygous for variant
1679 T > G experienced grade 4 diarrhea related to treat-
ment at week 3 and was withdrawn.
Downstaging, pathologic response, and sphincter
preservation
EUS was available pre- and posttreatment for 66 patients
and was interpretable in 52 evaluable patients (61%). Post-
chemotherapy uTN staging was in agreement with dou-
ble-checked pTN staging in 26 of 52 patients (50%) (Table
3). Pretreatment uTNM staging was compared with post-
chemoradiotherapy pTN staging (Table 4) and a signifi-
cant shift towards earlier TNM stages was observed (p <
0.001). Downstaging of the primary tumor occurred in
22/52 patients (42%) and downstaging of the lymph nodes
occurred in 23/52 patients (44%). In the 46 patients asses-
sable for T and N stage, 11 patients (24%) had downstaged
tumor and nodes, 11 patients (24%) had downstaged
nodes only, nine patients (20%) had downstaged tumor
only, and there was no difference in T or N staging in
15 patients (33%). The overall downstaging rate was 44%
for primary tumors and 48% for lymph nodes. A centra-
lized second pathologic examination performed in 78
patients confirmed the initial pTN results in 77% of cases.
Table 1 Baseline patient characteristics
Parameter Number of patients (%)
N=8 5
Age (years)
Median 67.1
Range 25-81
Gender
Male 56 (66)
Female 29 (34)
Clinical TNM stage
T3 85 (100)
N0 47 (55)
N1 33 (39)
N2 2 (2)
Unknown 3 (4)
Tumor staging method
EUS 66 (78)
Rigid rectoscopy 11 (13)
Other 7 (8)
Unknown 1 (1)
Distance from anal verge
>5 cm 50 (59)
≤5 cm 32 (38)
Unknown 3 (4)
WHO performance status
0 75 (88)
1 9 (11)
Unknown 1 (1)
TNM = tumor node metastasis.
WHO = World Health Organization.
Table 2 Acute adverse events that occurred during
preoperative chemoradiotherapy
Number of patients (%)
N=8 5
Adverse event Grade 3 Grade 4
Diarrhea 14 (17) 4 (5)
Nausea/vomiting 4 (5) 1 (1)
Cerebrovascular event 0 2 (2)
Proctitis 1 (1) 0
Radiocystitis 1 (1) 0
Radiodermatitis 2 (2) 0
Anemia 1 (1) 0
Leukopenia 0 1 (1)
Neutropenia 0 1 (1)
Hand-foot syndrome 0 0
Mucositis 1 (1) 0
Subocclusive syndrome 1 (1) 0
Second-degree cutaneous burns* 1 (1) 0
Epistaxis 1 (1) 0
Pneumopathy 1 (1) 0
Thrombophlebitis 1 (1) 0
Total 29 (34) 8 (9)
1. *Not related to treatment.
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understaged (four pT0, three pT1, two pT2, and one pT3),
and for three patients it was overstaged (two pT2 and one
pT4). Two patients with nonspecified T stage were classi-
fied pT3. In seven patients, malignant cells were undetect-
able in both the primary tumor and lymph nodes giving a
pCR rate of 8%. Ten patients (12%) had some microscopic
residual disease (Tmic).
Anal sphincter function was preserved in 55 patients
(65%). Five of 60 patients initially deemed suitable for
anterior resection (AR) had an abdominoperineal resection
(APR) (8% of planned resections) and two of 23 patients
whose planned surgery was APR underwent an AR (9% of
planned resections). APR was performed in 60% of
patients (n = 21) with a tumor in the distal third of the
rectum and in 9% of patients (n = 4) with a tumor in the
middle third of the rectum (within 6-8 cm of the pectineal
line) due to an overestimated distance to the anal verge
and to infiltration of the surgical border. AR was per-
formed in 87% of patients (n = 41) with a tumor in the
middle third of the rectum and in 40% of those whose
tumor was in the distal third (n = 14) (unknown pectineal
line n = 2, inextirpable n = 2). Perioperative and 30-day
postoperative complications included anastomotic leakage
(n = 1), perineal complications (n = 1), bleeding (n = 1),
ileus (n = 1), fistula (n = 1), and death (n = 2).
Survival and recurrence
The mean follow-up time was 45 months (range 1 - 84
months; one patient was lost to follow-up). OS was
92.6% at 1 year 86.1% at 2 years and 83.2% at 3 years;
mean recurrence-free survival was 39 ± 24 months.
Recurrence free survival was 81.9% at 1 year, 70.7% at 2
years and 66.7% at 3 years.
Two patients died within 18 days of surgery (one had
a pulmonary embolism and the other had a cerebrovas-
cular stroke). Sixteen other patients died during the
study: twelwe due to progressive disease; one due to dia-
betic decompensation, one due to vascular cerebral
stroke that occurred before surgery, and one due to
acute pulmonary failure and one due to a fall.
The level of local control in the 81 patients who
underwent surgery was 95%, with four patients (5%)
having local recurrence and 20 (24.7%) having secondary
metastases. Regardless of location, relapse generally
occurred <1 year after surgery (mean: 346 ± 236 days).
Adjuvant chemotherapy
Following surgery, 36 of 79 eligible patients (46%)
received adjuvant chemotherapy (mean duration 118 ±
65.8 days): 21 patients (58%) received 5-FU-based che-
motherapy, 10 (28%) received UFT-based chemotherapy
and 4 (11) received oxaliplatin-based chemotherapy. Six
patients had further chemotherapy for metastatic disease
within 4 months of surgery.
Discussion
Preoperative radiotherapy with or without i.v. 5-FU is a
reference treatment for patients with rectal cancer. The
aim of the present study was to evaluate the efficacy and
tolerability of the combination of UFT-based chemother-
apy and radiotherapy before resection. We found a signif-
icant downstaging rate (44% for primary tumors and 48%
for lymph nodes) similar to capecitabine [29] (Kim et al,
2007). The pCR rate was 8%, which is similar to that pre-
viously reported [11,30,31] (Fernández-Martos et al,
2004; Sauer et al, 2004; Durnst et al, 2008). The sphincter
preservation rate was also high (65%). The 2-year OS rate
was 80%, with 75% of patients free from recurrence, and
the rate of local relapse was 5%. These results are similar
to those obtained in other trials, many of which used
more aggressive regimens, such as combination oxalipla-
tin and fluoropyrimidine-based chemoradiotherapy
[32-34] (Sebag-Montefiore et al, 2005; Calvo et al, 2006;
Ryan et al, 2006).
Although the primary objective of this study was to
determine the downstaging of tumor and lymph nodes
by comparing EUS before and after chemoradiotherapy,
we decided to compare the initial EUS to pathological
findings. The accuracy of EUS, which was mandatory
for pretreatment evaluation in our study, has been
Table 3 Post-treatment EUS T staging and pathologic
analysis T staging
Pathologic analysis
Number of patients (%) T0 T2 T3 Total
EUS T0 3 (43) - 4 (57) 7
T1 1 (50) - 1 (50) 2
T2 3 (20) 4 (27) 8 (53) 15
T3 - 8 (30) 19 (70) 27
Total 7 12 32 51
EUS = endorectal ultrasonography.
Table 4 Pre-treatment EUS T and N staging and post-
treatment pathologic T and N staging in resected patients
Pre-treatment Post-treatment pathologic
stage
Downstaging, n/N (%)
EUS T stage pT0 pT1 pT2 pT3
T2* 1 0 2 0 1/3 (33)
T3 6 2 13 28 21/49 (43)
Total 7 2 15 28 22/52 (42)
EUS N stage pN0 pN1
N0 19 0 0/19
N1 22 10 22/32 (69)
N2 0 1 1/1 (100)
Total 41 11 23/52 (44)
EUS = endorectal ultrasonography.
*Three patients had an estimated T2 tumor using EUS but had a T3 tumor
identified clinically.
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rectal wall penetration and 23% for the determination of
nodal status [35,36] (Janjan et al, 1999; Chan et al,
2005). However, EUS is not possible in circumferential
tumors with stenosis and it is generally difficult to inter-
pret 6 weeks after completion of chemoradiotherapy. In
addition, EUS is highly dependent on the operator and
consistency of results can be an issue in multicenter
trials. The nonspecific inflammatory effects and deep
alterations evident in tissue architecture after chemora-
diotherapy make this examination useless after treat-
ment, despite its importance in determining the extent
of the tumor before surgery. Thus, we compared the
initial echoendoscopy with t h ep a t h o l o g i ce x a m[ 3 7 , 3 8 ]
(Chan et al, 2005; Mawdsley et al, 2005). Sensitivity and
specificity were not good even at the first pretreatment
examination: some tumors initially staged as T0 or T1
by EUS were found to be T3 on pathologic examination.
B a s e do ne v i d e n c ef r o mt h el i t e r a t u r ea n do u ro w n
experience, the current practice in our institutions is to
use magnetic resonance imaging for the evaluation of
local and regional tumor extension, as it provides more
precise and reliable results [38,39] (Rasheed et al,2 0 0 6 ;
Muthusamy et al, 2007).
The tolerability of the UFT chemoradiotherapy was
acceptable and diarrhea, as expected, was the most com-
mon adverse event. Two patients with heterozygous var-
iants (IVS14+1G > A and 2846A > T) plus the phenotype
of major enzyme deficiency experienced grade 4 neutro-
penia and diarrhea. At the time this study was underta-
ken, no data were available to link specific DPD
deficiencies and severe UFT-related adverse events.
Therefore, no dose adjustments were specified in the
protocol for patients with particular gene variations, and
two patients had grade 4 adverse events that might have
been avoided. Armed with this information, however, we
now systematically test for DPD by both DPD gene var-
iants and UH2:U ratio before beginning UFT-based treat-
m e n ta n dr e d u c et h eU F Td o s ei np a t i e n t sw i t hm a j o r
enzyme deficiencies as we do for all i.v. and oral fluoro-
pyrimidine therapy [26] (Boisdron-Celle et al, 2007).
The pattern of relapse in patients with locally advanced
rectal cancer and the tolerability of treatment [37,38]
(Mawdsley et al, 2005; Rasheed et al, 2006) call into
question the approach to preoperative intensification of
chemoradiotherapy currently under investigation else-
where. In our study, only 5% of patients experienced a
local relapse similar to that observed by other authors
[40,41] (Gérard et al, 2006; Bosset et al, 2006).
On the other hand, 15% of the patients died due to dis-
tant secondary metastases. Thus, the challenge that
remains following chemoradiotherapy for locally advanced
rectal cancer is to control distant metastases. In colon can-
cer, the risk of distant metastasis is reduced with adjuvant
chemotherapy and this might also apply to the rectal can-
cer setting. Many authors have emphasized the negative
impact of neoadjuvant chemoradiotherapy toxicity on
compliance with and tolerability of adjuvant chemotherapy
[42,43] (Rodríguez-Ramírez et al, 2006; Urso et al, 2006).
In our study, the mean duration of adjuvant chemotherapy
was 4 months, somewhat less than the 6 months usually
planned for other tumors, even though UFT has a favor-
able tolerability profile, better than the other combinations
usually reported. Our opinion is that patients would gain
more benefit from an efficient adjuvant or perhaps neoad-
juvant combination therapy than an intensification of
chemoradiotherapy by adding a cytotoxic drug to a fluoro-
pyrimidine [44,45] (Chen et al, 2007; Bosset et al, 2008).
Interest in preoperative chemoradiotherapy for patients
with locally advanced rectal cancer is due to the potential
for tumor downstaging, which increases the likelihood of
curative surgery and allows sphincter preservation in
many patients with low-lying tumors. UFT has the advan-
tage of convenient oral administration and a very good tol-
erability profile, with no hand-foot syndrome.
The efficacy and tolerability of UFT-based chemora-
diotherapy reported here are comparable with those pre-
viously reported for other fluoropyrimidines and much
better than those reported with cytotoxic drug combina-
tions. In addition, detection of DPD deficiency, which is
legally recommended for all fluoropyrimidines, has the
potential to allow identification of patients with clini-
cally relevant enzyme deficiencies and prevent severe
acute adverse events related to this condition.
Conclusion
Although EUS post chemoradiotherapy failled to assess
downstaging, preoperative UFT is an effective, well tol-
erated, and convenient treatment option for patients
with locally advanced rectal cancer.
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